Interní Med. 2007; 9(2): 67-69

When to consider cardiotoxicity of oncology treatment and how to diagnose it

MUDr. Jan M. Horáček Ph.D1,2
1 II. interní klinika, odd. klinické hematologie FN Hradec Králové
2 Katedra válečného vnitřního lékařství VLA J. E. Purkyně, Hradec Králové

The article treats the problems of cardiotoxicity of antitumorous treatment. The most frequent causes and signs of cardiotoxicity of treatment in oncology are briefly mentioned. Moreover, the present-day diagnostic methods of cardiotoxicity are reviewed. The role and potential of biochemical markers of heart damage is pointed out. Recently, biochemical markers of heart damage are intensively studied, not only in this particular indication.

Keywords: Keywords: cardiotoxicity, antitumorous treatment, diagnostics, biochemical markers.

Published: March 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Horáček JM. When to consider cardiotoxicity of oncology treatment and how to diagnose it. Interní Med. 2007;9(2):67-69.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Adamcova M, Sterba M, Simunek T, et al. Troponin as a marker of myocardiac damage in drug-induced cardiotoxicity. Expert Opin Drug Saf 2005; 4: 457-472. Go to original source... Go to PubMed...
    2. Aschermann M, et al. Kardiologie. 1. vyd. Praha: Galén 2004. 1481 s.
    3. Auner HW, Tinchon C, Linkesch W, et al. Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignancies. Ann Hematol 2003; 82: 218-222. Go to original source... Go to PubMed...
    4. Bauch M, Ester A, Kimura B, et al. Atrial natriuretic peptide as a marker for doxorubicin-induced cardiotoxic effects. Cancer 1992; 69: 1492-1497. Go to original source...
    5. Cardinale D, Sandri MT, Colombo A, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 2004; 109: 2749-2754. Go to original source... Go to PubMed...
    6. Cowie MR, Jourdain P, Maisel A, et al. Clinical applications of B-type natriuretic peptide (BNP) testing. Eur Heart J 2003; 24: 1710-1718. Go to original source... Go to PubMed...
    7. Elbl L, et al. Poškození srdce protinádorovou léčbou. 1. vyd. Praha: Grada Publishing 2002. 156 s.
    8. Davis MJ, Rowley DS, Braine HG, et al. Clinical toxicity of cryopreserved bone marrow graft infusion. Blood 1990; 75: 781-786. Go to original source...
    9. Fink FM, Genser N, Fink C, et al. Cardiac troponin T and creatine kinase MB mass concentrations in children receiving anthracycline chemotherapy. Med. Pediatr Oncol 1995; 25: 185-189. Go to original source... Go to PubMed...
    10. Ganz WI, Sridhar KS, Ganz SS, et al. Review of tests for monitoring doxorubicin-induced cardiomyopathy. Oncology 1996; 53: 461-470. Go to original source... Go to PubMed...
    11. Kilickap S, Barista I, Akgul E, et al. cTnT can be a useful marker for early detection of anthracycline cardiotoxicity. Ann Oncol 2005; 16: 798-804. Go to original source... Go to PubMed...
    12. Meinardi MT, Van der Graaf WTA, Van Veldhuisen DJ, et al. Detection of anthracycline-induced cardiotoxicity. Cancer Treat Rev 1999; 25: 237-247. Go to original source... Go to PubMed...
    13. Okumura H, Iuchi K, Yoshida T, et al. Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity. Acta Haematol 2000; 104: 158-163. Go to original source... Go to PubMed...
    14. Petersen FB, Bearman SI. Preparative regimens and their toxicity. In: Forman SJ, Blume KG, Thomas ED. Bone marrow transplantation. Boston: Blackwell Scientific Publications 1994: 79-83.
    15. Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001; 22: 1527-1560. Go to original source... Go to PubMed...
    16. Sandri MT, Salvatici M, Cardinale D, et al. N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction? Clin Chem 2005; 51: 1405-1410. Go to original source... Go to PubMed...
    17. Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Ann Intern Med 1996; 125: 47-58. Go to original source... Go to PubMed...
    18. Snowden JA, Hill GR, Hunt P, et al. Assessment of cardiotoxicity during haemopoietic stem cell transplantation with plasma brain natriuretic peptide. Bone Marrow Transplant 2000; 26: 309-313. Go to original source... Go to PubMed...
    19. Suzuki T, Hayashi D, Yamazaki T, et al. Elevated B-type natriuretic peptide levels after anthracycline administration. Am Heart J 1998; 136: 362-363. Go to original source... Go to PubMed...
    20. Yeh ET, Tong AT, Lenihan DJ. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis and management. Circulation 2004; 109: 3122-3131. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.